

04/06/01

04 - 09 - 01

Please type a plus sign (+) inside this box

十

PTO/SB/05 (11-00)
Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a valid OMB control number.

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	RDC 12320 Div.
First Inventor	EDA
Title	Microparticle Enhanced Scattering..
Express Mail Label No.	EJ239781878US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. <input checked="" type="checkbox"/>	Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)
2. <input type="checkbox"/>	Applicant claims small entity status. See 37 CFR 1.27.
3. <input checked="" type="checkbox"/>	Specification [Total Pages 58] (preferred arrangement set forth below) <ul style="list-style-type: none"> - Descriptive title of the invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (<i>if filed</i>) - Detailed Description - Claim(s) - Abstract of the Disclosure
4. <input checked="" type="checkbox"/>	Drawing(s) (35 U.S.C. 113) [Total Sheets 8]
5. Oath or Declaration	[Total Pages]
a. <input type="checkbox"/>	Newly executed (original or copy)
b. <input checked="" type="checkbox"/>	Copy from a prior application (37 CFR 1.63 (d)) (<i>for continuation/divisional with Box 18 completed</i>)
i. <input type="checkbox"/>	<u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. <input type="checkbox"/>	Application Data Sheet. See 37 CFR 1.76

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

7. CD-ROM or CD-R in duplicate, large table or Computer Program (*Appendix*)

8. Nucleotide and/or Amino Acid Sequence Submission (*if applicable, all necessary*)

- Computer Readable Form (CRF)
- Specification Sequence Listing on:
 - CD-ROM or CD-R (2 copies); or
 - paper
- Statements verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

9. Assignment Papers (cover sheet & document(s))

10. 37 CFR 3.73(b) Statement Power of Attorney
(when there is an assignee)

11. English Translation Document *(if applicable)*

12. Information Disclosure Statement (IDS)/PTO-1449 Copies of IDS
 Citations

13. Preliminary Amendment

14. Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)

15. Certified Copy of Priority Document(s)
(if foreign priority is claimed)

16. Request and Certification under 35 U.S.C. 122
(b)(2)(B)(i). Applicant must attach form PTO/SB/35
or its equivalent.

17. Other:

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

Continuation Divisional Continuation-in-part (CIP)

of prior application No.: 09/129,744

Prior application information:

Examiner Gabel, G.

Group Ad Unit: 1641

Group A10. 100

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

19. CORRESPONDENCE ADDRESS

<input checked="" type="checkbox"/> Customer Number or Bar Code Label	26345 (Insert Customer No. or Attach bar code label here)	or <input type="checkbox"/>	Correspondence address below
Name			
Address			
City	State	Zip Code	
Country	Telephone	Fax	
Name (Print/Type)	Kristine L. Butler	Registration No. (Attorney/Agent)	42,376
Signature		Date	April 6, 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$ 728.00)

Complete if Known

Application Number	09/129,744
Filing Date	08/05/1998
First Named Inventor	Eda
Examiner Name	Gabel, G.
Group Art Unit	1641
Attorney Docket No.	RDC 12320 Div.

METHOD OF PAYMENT

1. The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number 03-3839
Deposit Account Name Gibbons, Del Deo, Dolan

Charge Any Additional Fee Required
Under 37 CFR 1.16 and 1.17
 Applicant claims small entity status.
See 37 CFR 1.27

2. Payment Enclosed:

Check Credit card Money Order Other

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee (\$)	Fee Code (\$)	Fee (\$)	Fee Description	Fee Paid
105	130	205	65	65	Surcharge - late filing fee or oath	
127	50	227	25	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	130	Non-English specification	
147	2,520	147	2,520	2,520	For filing a request for ex parte reexamination	
112	920*	112	920*	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	55	Extension for reply within first month	
116	390	216	195	195	Extension for reply within second month	
117	890	217	445	445	Extension for reply within third month	
118	1,390	218	695	695	Extension for reply within fourth month	
128	1,890	228	945	945	Extension for reply within fifth month	
119	310	219	155	155	Notice of Appeal	
120	310	220	155	155	Filing a brief in support of an appeal	
121	270	221	135	135	Request for oral hearing	
138	1,510	138	1,510	1,510	Petition to institute a public use proceeding	
140	110	240	55	55	Petition to revive - unavoidable	
141	1,240	241	620	620	Petition to revive - unintentional	
142	1,240	242	620	620	Utility issue fee (or reissue)	
143	440	243	220	220	Design issue fee	
144	600	244	300	300	Plant issue fee	
122	130	122	130	130	Petitions to the Commissioner	
123	50	123	50	50	Processing fee under 37 CFR 1.17(q)	
126	180	126	180	180	Submission of Information Disclosure Stmt	
581	40	581	40	40	Recording each patent assignment per property (times number of properties)	
146	710	246	355	355	Filing a submission after final rejection (37 CFR § 1.129(a))	
149	710	249	355	355	For each additional invention to be examined (37 CFR § 1.129(b))	
179	710	279	355	355	Request for Continued Examination (RCE)	
169	900	169	900	900	Request for expedited examination of a design application	
Other fee (specify) _____						
*Reduced by Basic Filing Fee Paid						SUBTOTAL (3) (\$ 0)

*or number previously paid, if greater; For Reissues, see above

SUBMITTED BY		Complete if applicable		
Name (Print/Type)	Kristine L. Butler	Registration No. (Attorney/Agent)	42,376	Telephone 973-596-4683
Signature		Date	04/06/2001	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Shinichi Eda, et al.Application No./Patent No.: 09/129,744 Filed/Issue Date: August 5, 1998Entitled: Microparticle Enhanced Light Scattering Agglutination Assay And Microparticle Reagents ThereforROCHE DIAGNOSTICS CORPORATION, a Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

- the assignee of the entire right, title, and interest; or
- an assignee of an undivided part interest

in the patent application/patent identified above by virtue of either:

A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel , Frame , or for which a copy thereof is attached.

OR

B. A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

Shinichi Eda, Jorg Heinrich

1. From: Kaufmann & Stefan Pohl To: F. Hoffmann-La Roche AG
The document was recorded in the Patent and Trademark Office at Reel 9434, Frame 0825, or for which a copy thereof is attached.
2. From: F. Hoffmann-La Roche AG To: Roche Diagnostic Systems, Inc.
The document was recorded in the Patent and Trademark Office at Reel 9434, Frame 0835, or for which a copy thereof is attached.
3. From: Roche Diagnostic Systems, Inc. To: Roche Diagnostics Corporation
The document was recorded in the Patent and Trademark Office at Reel 9720, Frame 0023, or for which a copy thereof is attached.

 Additional documents in the chain of title are listed on a supplemental sheet. Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the PTO. See MPEP 302-302.8.

The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee.

8/19/99
DateSteve A. Oldham
SignatureSteve A. Oldham
Typed or printed name

 The logo for Roche Diagnostics, featuring the word "Roche" in a stylized font inside a hexagon, with "Diagnostics" written vertically below it.
Vice President and General Counsel

Title